Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Cancer and Oncology›Basal Cell Carcinoma
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Basal Cell Carcinoma

Cancer and Oncology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (888 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 3d ed, p1471)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Basal Cell Epithelioma; Rodent Ulcer; Rodent Ulcers; Ulcers, Rodent; Carcinoma, Basal Cell; Pigmented Basal Cell Carcinoma.

Where it fits in the MeSH classification

Broader topics
Non-Melanoma Skin Neoplasms; Neoplasms, Basal Cell
Narrower topics
Basal Cell Nevus Syndrome

Research landscape

PubMed indexes 20,891 records tagged with the MeSH heading “Basal Cell Carcinoma” (counts retrieved 2026-10-29). 3,068 of them (14.7%) were published from 2020 onward, and the busiest period so far is through 1999 with 8,160 records.

Reviews account for 2,367 records (11.3%) and meta-analyses for 126. Randomized controlled trials number 279 (1.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 8,160 records; 2000-2009: 3,999 records; 2010-2019: 5,664 records; 2020 onward: 3,068 records8,160through 19993,9992000-20095,6642010-20193,0682020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19998,160
2000-20093,999
2010-20195,664
2020 onward3,068
Share of records by publication typeReviews: 11.3 percent; Meta-analyses: 0.6 percent; Randomized controlled trials: 1.3 percentReviews11.3% (2,367)Meta-analyses0.6% (126)Randomized controlled trials1.3% (279)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 20,891 PubMed records
TypeRecordsShare
Reviews2,36711.3%
Meta-analyses1260.6%
Randomized controlled trials2791.3%

Method: PubMed query "Basal Cell Carcinoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in cancer and oncology

Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma
Ganier C, Mazin P, Herrera-Oropeza G, Du-Harpur X, Blakeley M, Gabriel J, et al.
2024Research article
Design not recorded in structured metadata
61cc by
PMID 38165934 · DOI · PMC10786309
Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma
Schütz S, Solé-Boldo L, Lucena-Porcel C, Hoffmann J, Brobeil A, Lonsdorf AS, et al.
2023Research article
Design not recorded in structured metadata
49cc by
PMID 37669956 · DOI · PMC10480447
Emerging Roles of Hedgehog Signaling in Cancer Immunity
Giammona A, Crivaro E, Stecca B
2023Review article
Design not recorded in structured metadata
45cc by
PMID 36674836 · DOI · PMC9864846
Weakly supervised deep learning for cutaneous squamous and basal cell carcinoma in whole-slide histopathology
Petzold A, Wessely A, Schliep S, Jiang H, Tran M, Koch EA, et al.
2026Research article
Design not recorded in structured metadata
2cc by
PMID 41841638 · DOI · PMC13093612

Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma [1]

Research article Ganier C, Mazin P, Herrera-Oropeza G, Du-Harpur X, Blakeley M, Gabriel J, et al. · · 2024 · cited 61 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Our understanding of how human skin cells differ according to anatomical site and tumour formation is limited.
Closing excerpt
The resource we have created is publicly available in an interactive format for the research community.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (185 words)

Our understanding of how human skin cells differ according to anatomical site and tumour formation is limited. To address this, we have created a multiscale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating in vivo optical coherence tomography, single-cell RNA sequencing, spatial global transcriptional profiling, and in situ sequencing. Computational spatial deconvolution and projection revealed the localisation of distinct cell populations to specific tissue contexts. Although cell populations were conserved between healthy anatomical sites and in BCC, mesenchymal cell populations including fibroblasts and pericytes retained signatures of developmental origin. Spatial profiling and in silico lineage tracing support a hair follicle origin for BCC and demonstrate that cancer-associated fibroblasts are an expansion of a POSTN+ subpopulation associated with hair follicles in healthy skin. RGS5+ pericytes are also expanded in BCC suggesting a role in vascular remodelling. We propose that the identity of mesenchymal cell populations is regulated by signals emanating from adjacent structures and that these signals are repurposed to promote the expansion of skin cancer stroma. The resource we have created is publicly available in an interactive format for the research community.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38165934 · DOI · PMC10786309

Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma [2]

Research article Schütz S, Solé-Boldo L, Lucena-Porcel C, Hoffmann J, Brobeil A, Lonsdorf AS, et al. · · 2023 · cited 49 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Cutaneous squamous cell carcinoma (cSCC) is a serious public health problem due to its high incidence and metastatic potential.
Closing excerpt
Our study provides important insights into the potential origin and functionalities of dermal CAFs that will be highly beneficial for the specific targeting of the cSCC microenvironment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (151 words)

Cutaneous squamous cell carcinoma (cSCC) is a serious public health problem due to its high incidence and metastatic potential. It may progress from actinic keratosis (AK), a precancerous lesion, or the in situ carcinoma, Bowen's disease (BD). During this progression, malignant keratinocytes activate dermal fibroblasts into tumor promoting cancer-associated fibroblasts (CAFs), whose origin and emergence remain largely unknown. Here, we generate and analyze >115,000 single-cell transcriptomes from healthy skin, BD and cSCC of male donors. Our results reveal immunoregulatory and matrix-remodeling CAF subtypes that may derive from pro-inflammatory and mesenchymal fibroblasts, respectively. These CAF subtypes are largely absent in AK and interact with different cell types to establish a pro-tumorigenic microenvironment. These findings are cSCC-specific and could not be recapitulated in basal cell carcinomas. Our study provides important insights into the potential origin and functionalities of dermal CAFs that will be highly beneficial for the specific targeting of the cSCC microenvironment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37669956 · DOI · PMC10480447

Emerging Roles of Hedgehog Signaling in Cancer Immunity [3]

Review article Giammona A, Crivaro E, Stecca B · · 2023 · cited 45 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Hedgehog-GLI (HH) signaling plays an essential role in embryogenesis and tissue homeostasis.
Closing excerpt
In addition, we discuss the future prospect of therapeutic options combining the HH pathway and immune checkpoint inhibitors.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (195 words)

Hedgehog-GLI (HH) signaling plays an essential role in embryogenesis and tissue homeostasis. Aberrant activation of the pathway through mutations or other mechanisms is involved in the development and progression of numerous types of cancer, including basal cell carcinoma, medulloblastoma, melanoma, breast, prostate, hepatocellular and pancreatic carcinomas. Activation of HH signaling sustains proliferation, suppresses cell death signals, enhances invasion and metastasis, deregulates cellular metabolism and promotes angiogenesis and tumor inflammation. Targeted inhibition of the HH pathway has therefore emerged as an attractive therapeutic strategy for the treatment of a wide range of cancers. Currently, the Smoothened (SMO) receptor and the downstream GLI transcriptional factors have been investigated for the development of targeted drugs. Recent studies have revealed that the HH signaling is also involved in tumor immune evasion and poor responses to cancer immunotherapy. Here we focus on the effects of HH signaling on the major cellular components of the adaptive and innate immune systems, and we present recent discoveries elucidating how the immunosuppressive function of the HH pathway is engaged by cancer cells to prevent immune surveillance. In addition, we discuss the future prospect of therapeutic options combining the HH pathway and immune checkpoint inhibitors.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36674836 · DOI · PMC9864846

Weakly supervised deep learning for cutaneous squamous and basal cell carcinoma in whole-slide histopathology [4]

Research article Petzold A, Wessely A, Schliep S, Jiang H, Tran M, Koch EA, et al. · · 2026 · cited 2 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Distinguishing infiltrative basal cell carcinoma (BCC) from poorly differentiated cutaneous squamous cell carcinoma (cSCC) remains a significant histopathological challenge.
Closing excerpt
However, reliable deployment across institutions necessitates careful calibration and domain adaptation, and even powerful foundation models such as HistoGPT benefit from targeted fine-tuning to ensure robust performance in dermatopathology.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (357 words)

Distinguishing infiltrative basal cell carcinoma (BCC) from poorly differentiated cutaneous squamous cell carcinoma (cSCC) remains a significant histopathological challenge. Automated deep learning approaches hold promise for improving diagnostic reliability, yet robust external validation is essential. In this study, we developed a weakly supervised deep learning model to classify these diagnostically challenging subtypes and evaluated its generalizability across internal and external cohorts, as well as in comparison to a dermatopathology foundation model (HistoGPT). The model employed a multiple-instance learning framework (CLAM) using the histopathology-specific transformer Phikon for feature extraction from whole-slide images. Slide-level ground-truth diagnoses from the collected images (n = 335, University Hospital Erlangen) were derived from routine clinical practice and re-evaluated by two board-certified dermatopathologists. Performance was assessed on an internal test set of 84 whole-slide images (27 cSCC and 57 BCC) and two external datasets: Queensland cohort (n = 10, curated in-distribution cases) and the COBRA cohort (n = 200, broad, partly out-of-distribution cases). Model discrimination was quantified using ROC curves, while accuracy, sensitivity, and specificity were reported alongside 95% Wilson confidence intervals (CIs). On the internal test set, the model achieved perfect classification [area under the receiver operating characteristic (AUC) = 1.0; 100% accuracy, sensitivity, and specificity]. Similarly, strong performance was observed in the Queensland cohort (AUC = 1.0), although limited by sample size. In the more heterogeneous COBRA cohort, discrimination remained high (AUC = 0.923, 95% CI 0.885-0.961), requiring threshold adjustment to correct for marked calibration shift (balanced accuracy 86.5% at Youden's J). Attention heatmaps highlighted histologically meaningful regions. In zero-shot evaluation on the internal test set, HistoGPT achieved an overall accuracy of 77%, with high class-wise sensitivity for BCC (98%, 95% CI 91-100) but markedly reduced sensitivity for cSCC (33%, 95% CI 19-52). Fine-tuning a task-specific classifier on the HistoGPT backbone substantially improved performance, achieving near-perfect discrimination and 98% balanced accuracy. These findings demonstrate that weakly supervised deep learning enables highly accurate classification of diagnostically challenging BCC and cutaneous squamous cell carcinoma subtypes. However, reliable deployment across institutions necessitates careful calibration and domain adaptation, and even powerful foundation models such as HistoGPT benefit from targeted fine-tuning to ensure robust performance in dermatopathology.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41841638 · DOI · PMC13093612

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 [5]
    Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. · Eur J Cancer · 2023 · cited 223 times (Europe PMC)
  • Research article Understanding the Molecular Genetics of Basal Cell Carcinoma [6]
    Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC · Int J Mol Sci · 2017 · cited 161 times (Europe PMC)
  • Research article Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline [7]
    Likhacheva A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, et al. · Pract Radiat Oncol · 2020 · cited 156 times (Europe PMC)
  • Research article Basal Cell Carcinoma Review [8]
    Kim DP, Kus KJB, Ruiz E · Hematol Oncol Clin North Am · 2019 · cited 131 times (Europe PMC)
  • Research article Non-Melanoma Skin Cancers: Biological and Clinical Features [9]
    Cives M, Mannavola F, Lospalluti L, Sergi MC, Cazzato G, Filoni E, et al. · Int J Mol Sci · 2020 · cited 131 times (Europe PMC)
  • Research article Basal Cell Carcinoma: A Comprehensive Review [10]
    Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al. · Int J Mol Sci · 2020 · cited 128 times (Europe PMC)

References

  1. Ganier C, Mazin P, Herrera-Oropeza G, Du-Harpur X, Blakeley M, Gabriel J, et al.. Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma. . 2024. PMID 38165934 · DOI · PMC10786309
  2. Schütz S, Solé-Boldo L, Lucena-Porcel C, Hoffmann J, Brobeil A, Lonsdorf AS, et al.. Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma. . 2023. PMID 37669956 · DOI · PMC10480447
  3. Giammona A, Crivaro E, Stecca B. Emerging Roles of Hedgehog Signaling in Cancer Immunity. . 2023. PMID 36674836 · DOI · PMC9864846
  4. Petzold A, Wessely A, Schliep S, Jiang H, Tran M, Koch EA, et al.. Weakly supervised deep learning for cutaneous squamous and basal cell carcinoma in whole-slide histopathology. . 2026. PMID 41841638 · DOI · PMC13093612
  5. Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al.. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023. PMID 37604067 · DOI
  6. Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC. Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci. 2017. PMID 29165358 · DOI · PMC5713451
  7. Likhacheva A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, et al.. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020. PMID 31831330 · DOI
  8. Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2019. PMID 30497670 · DOI
  9. Cives M, Mannavola F, Lospalluti L, Sergi MC, Cazzato G, Filoni E, et al.. Non-Melanoma Skin Cancers: Biological and Clinical Features. Int J Mol Sci. 2020. PMID 32751327 · DOI · PMC7432795
  10. Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al.. Basal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci. 2020. PMID 32759706 · DOI · PMC7432343

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Cutaneous Squamous Cell CarcinomaCancer and Oncology
  • Cutaneous Malignant MelanomaCancer and Oncology
  • MelanomaCancer and Oncology
  • Esophageal Squamous Cell CarcinomaCancer and Oncology
  • CarcinomaCancer and Oncology
  • Carcinoma in SituCancer and Oncology

All 107 articles in Cancer and Oncology →

At a glance

20,891
PubMed records on this heading
15%
published since 2020
2,367
review articles
279
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Cutaneous Squamous Cell CarcinomaCancer and Oncology
  • Cutaneous Malignant MelanomaCancer and Oncology
  • MelanomaCancer and Oncology
  • Esophageal Squamous Cell CarcinomaCancer and Oncology
  • CarcinomaCancer and Oncology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support